JP7017410B2 - ｉｎ ｖｉｖｏ画像化のためのプロテアーゼ活性化コントラスト剤 - Google Patents

ｉｎ ｖｉｖｏ画像化のためのプロテアーゼ活性化コントラスト剤 Download PDF

Info

Publication number
JP7017410B2
JP7017410B2 JP2017538686A JP2017538686A JP7017410B2 JP 7017410 B2 JP7017410 B2 JP 7017410B2 JP 2017538686 A JP2017538686 A JP 2017538686A JP 2017538686 A JP2017538686 A JP 2017538686A JP 7017410 B2 JP7017410 B2 JP 7017410B2
Authority
JP
Japan
Prior art keywords
compound according
item
quencher
alkyl
label
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017538686A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018511556A5 (https=
JP2018511556A (ja
Inventor
マシュー エス． ボギョ，
マーティン バードース，
レスリー オホリ，
ニマリ ピー． ウィットハナ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of JP2018511556A publication Critical patent/JP2018511556A/ja
Publication of JP2018511556A5 publication Critical patent/JP2018511556A5/ja
Priority to JP2022010930A priority Critical patent/JP2022044770A/ja
Application granted granted Critical
Publication of JP7017410B2 publication Critical patent/JP7017410B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2017538686A 2015-01-22 2016-01-22 ｉｎ ｖｉｖｏ画像化のためのプロテアーゼ活性化コントラスト剤 Active JP7017410B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022010930A JP2022044770A (ja) 2015-01-22 2022-01-27 ｉｎ ｖｉｖｏ画像化のためのプロテアーゼ活性化コントラスト剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562106400P 2015-01-22 2015-01-22
US62/106,400 2015-01-22
PCT/US2016/014606 WO2016118910A1 (en) 2015-01-22 2016-01-22 Protease-activated contrast agents for in vivo imaging

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022010930A Division JP2022044770A (ja) 2015-01-22 2022-01-27 ｉｎ ｖｉｖｏ画像化のためのプロテアーゼ活性化コントラスト剤

Publications (3)

Publication Number Publication Date
JP2018511556A JP2018511556A (ja) 2018-04-26
JP2018511556A5 JP2018511556A5 (https=) 2019-03-07
JP7017410B2 true JP7017410B2 (ja) 2022-02-08

Family

ID=56417841

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017538686A Active JP7017410B2 (ja) 2015-01-22 2016-01-22 ｉｎ ｖｉｖｏ画像化のためのプロテアーゼ活性化コントラスト剤
JP2022010930A Pending JP2022044770A (ja) 2015-01-22 2022-01-27 ｉｎ ｖｉｖｏ画像化のためのプロテアーゼ活性化コントラスト剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022010930A Pending JP2022044770A (ja) 2015-01-22 2022-01-27 ｉｎ ｖｉｖｏ画像化のためのプロテアーゼ活性化コントラスト剤

Country Status (6)

Country Link
US (3) US10570173B2 (https=)
EP (1) EP3247802B1 (https=)
JP (2) JP7017410B2 (https=)
KR (1) KR102668593B1 (https=)
CN (1) CN107406872B (https=)
WO (1) WO2016118910A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10570173B2 (en) * 2015-01-22 2020-02-25 The Board Of Trustees Of The Leland Stanford Junior University Protease-activated contrast agents for in vivo imaging
US10405753B2 (en) * 2015-11-10 2019-09-10 Intuitive Surgical Operations, Inc. Pharmaceutical compositions of near IR closed chain, sulfo-cyanine dyes
GB201617935D0 (en) 2016-10-24 2016-12-07 Queens University Of Belfast The Binding compound and uses thereof
JP6984909B2 (ja) * 2016-12-23 2021-12-22 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 活性ベースのプローブ化合物、組成物、および使用方法
KR102669535B1 (ko) * 2017-03-30 2024-05-24 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 생체 내 이미징을 위한 프로테아제 활성화 조영제
US20220105206A1 (en) * 2020-10-02 2022-04-07 Board Of Regents, The University Of Texas System Sensitivity advances in ultrasound switchable fluorescence systems and techniques

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010535167A (ja) 2007-08-03 2010-11-18 サノフィ−アベンティス カスパーゼイメージングプローブ
JP2012508233A (ja) 2008-11-07 2012-04-05 チルドレンズ ホスピタル メディカル センター 膜貫通薬物送達システムへの適用のためのサポシンｃ、並びに関連のタンパク質及びペプチドの融合性
JP2014111600A (ja) 2006-04-28 2014-06-19 Childrens Hospital Medical Center 膜貫通薬物送達システムに適用するためのプロサポシン由来の融合タンパク質又はポリペプチドを含む組成物
WO2014145257A2 (en) 2013-03-15 2014-09-18 The Board Of Trustees Of The Leland Stanford Junior University Activity-based probe compounds, compositions, and methods of use

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL60888A (en) * 1978-06-16 1984-07-31 Yeda Res & Dev Substrates and process for the quantitative assay of enzymes
WO1996041638A1 (en) 1995-06-13 1996-12-27 Sanofi Winthrop, Inc. Calpain inhibitors for the treatment of neurodegenerative diseases
US7303741B2 (en) 2002-09-23 2007-12-04 General Electric Company Systems and methods for high-resolution in vivo imaging of biochemical activity in a living organism
US8133482B2 (en) * 2003-11-14 2012-03-13 The Trustees Of The University Of Pennsylvania Activatable photodynamic therapy agents
JP2008522624A (ja) 2004-12-09 2008-07-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘミアスタリン（ｈｅｍｉａｓｔｅｒｌｉｎ）アナログを使用する癌治療におけるチューブリンのアイソタイプのスクリーニング
US8968700B2 (en) * 2005-08-11 2015-03-03 The Board Of Trustees Of The Leland Stanford Junior University Imaging of protease activity in live cells using activity based probes
CN101652149B (zh) * 2007-02-28 2012-11-14 塞诺菲-安万特股份有限公司 成像探针
WO2008104271A2 (en) 2007-02-28 2008-09-04 Sanofi-Aventis Imaging probes
CA2686089A1 (en) * 2007-05-16 2008-11-20 Ge Healthcare As Optical imaging agents
US8343458B2 (en) 2008-04-03 2013-01-01 The Board Of Trustees Of The Leland Stanford Junior University Probes for in vivo targeting of active cysteine proteases
WO2010016911A2 (en) * 2008-08-06 2010-02-11 The Texas A & M University System Use of bacterial beta-lactamase for in vitro diagnostics and in vivo imaging, diagnostics and therapeutics
US9155471B2 (en) * 2009-05-27 2015-10-13 Lumicell, Inc'. Methods and systems for spatially identifying abnormal cells
WO2012021800A2 (en) 2010-08-13 2012-02-16 Banyan Biomarkers Caspase inhibitors as therapeutics for neural and organ injury and imaging
WO2012118715A2 (en) 2011-02-28 2012-09-07 The Board Of Trustees Of Leland Stanford Junior University Non-peptidic quenched fluorescent imaging probes
EP2686680B1 (en) * 2011-03-18 2018-06-13 Biotium Inc. Fluorescent dyes, fluorescent dye kits, and methods of preparing labeled molecules
US20140249468A1 (en) * 2011-09-09 2014-09-04 The United States Of America,As Represented By The Secretary, Department Of Health And Human Service Imaging agents for imaging protease activity and uses thereof
US20140180073A1 (en) * 2012-12-24 2014-06-26 Anticancer, Inc. Portable digital imaging system for fluorescence-guided surgery
US9763577B2 (en) 2013-03-14 2017-09-19 Lumicell, Inc. Imaging agent for detection of diseased cells
SG11201508185YA (en) * 2013-04-19 2015-11-27 Agency Science Tech & Res Tunable fluorescence using cleavable linkers
US10570173B2 (en) * 2015-01-22 2020-02-25 The Board Of Trustees Of The Leland Stanford Junior University Protease-activated contrast agents for in vivo imaging
KR102669535B1 (ko) * 2017-03-30 2024-05-24 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 생체 내 이미징을 위한 프로테아제 활성화 조영제

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014111600A (ja) 2006-04-28 2014-06-19 Childrens Hospital Medical Center 膜貫通薬物送達システムに適用するためのプロサポシン由来の融合タンパク質又はポリペプチドを含む組成物
JP2010535167A (ja) 2007-08-03 2010-11-18 サノフィ−アベンティス カスパーゼイメージングプローブ
JP2012508233A (ja) 2008-11-07 2012-04-05 チルドレンズ ホスピタル メディカル センター 膜貫通薬物送達システムへの適用のためのサポシンｃ、並びに関連のタンパク質及びペプチドの融合性
WO2014145257A2 (en) 2013-03-15 2014-09-18 The Board Of Trustees Of The Leland Stanford Junior University Activity-based probe compounds, compositions, and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Oligonucleotide Labeling Reagents，AAT Bioquest(R)，2014年，pp. 1-40

Also Published As

Publication number Publication date
US20240025945A1 (en) 2024-01-25
KR20180010177A (ko) 2018-01-30
CN107406872B (zh) 2023-03-28
US10570173B2 (en) 2020-02-25
US20180002375A1 (en) 2018-01-04
US12459972B2 (en) 2025-11-04
US20200299327A1 (en) 2020-09-24
WO2016118910A1 (en) 2016-07-28
EP3247802A1 (en) 2017-11-29
EP3247802B1 (en) 2024-08-28
JP2022044770A (ja) 2022-03-17
JP2018511556A (ja) 2018-04-26
KR102668593B1 (ko) 2024-05-22
CN107406872A (zh) 2017-11-28
EP3247802A4 (en) 2018-08-22

Similar Documents

Publication Publication Date Title
JP2022044770A (ja) ｉｎ ｖｉｖｏ画像化のためのプロテアーゼ活性化コントラスト剤
JP7689753B2 (ja) 活性に基づくプローブの化合物、組成物、および使用方法
JP7720102B2 (ja) 活性ベースのプローブ化合物、組成物、および使用方法
US20240077475A1 (en) Protease-activated contrast agents for in vivo imaging
CN116217656B (zh) 基于活性的探针化合物、组合物及其使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200522

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210430

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210804

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211228

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220127

R150 Certificate of patent or registration of utility model

Ref document number: 7017410

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250